Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNEC30 is a nano-formulated curcumin product developed by Arbro Pharmaceuticals in collaboration with the Defense Research & Development Organization (DRDO) and Jamia Hamdard University. It utilizes a patented Self Nano-Emulsifying Drug Delivery System (SNEDDS) technology (US Patent No. US8835509) to overcome the inherent poor aqueous solubility and low bioavailability of curcumin, a polyphenol derived from turmeric (*Curcuma longa*). Curcumin acts as a natural anti-inflammatory agent and antioxidant, primarily through the inhibition of cyclooxygenase-2 (COX-2) and the scavenging of free radicals. SNEC30 is delivered as a liquid-filled hard gelatin capsule and is indicated for a wide range of pro-inflammatory conditions, including arthritis, psoriasis, diabetes, and liver health. Notably, it has been included in DRDO's Nuclear Biological & Chemical Warfare (NBC) Emergency Kit for its radioprotective properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SNEC30.